BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
BEGIN:VEVENT
DTSTAMP:20260902T234339Z
UID:d9702fc3-ab33-45a5-87f6-d5cd0b543cf5
DTSTART:20210927T160000Z
DTEND:20210927T180000Z
DESCRIPTION:In vitro immuno-nanotoxicological methods that take pre-existin
 g conditions into account\n\nAbtract:\n\nIn the workplace environment\, wh
 ere nanoparticles (NPs) may reach higher concentrations\, the co-existence
  of allergens may result in new combinations of NPs with allergens. Normal
  as well as pre-disposed individuals\, suffering from pre-existing allergi
 c sensitization\, may thus be affected by inhalation of aerosols carrying 
 these new combinations having different immunological consequences. Recent
 ly\, epithelial barrier integrity has been recognized to exert major impac
 ts on the general health status of humans (epithelial barrier hypothesis\,
  https://doi.org/10.1038/s41577-021-00538-7)\, responsible for increase in
  allergy\, autoimmunity and other chronic conditions. Moreover\, for thera
 peutic approaches allergens are conjugated with different types of particu
 late matter\, which serve as adjuvants\, to boost the immune reaction or\,
  in the particular case of allergen-specific immunotherapy\, to drive immu
 nomodulation from a type 2 to a more tolerogenic response. Here\, the vari
 ety of materials can range from classical alum-based to more sophisticated
  nanovaccine carriers. Decreasing the size-range into the nano-scale goes 
 in line with specific surface-related effects\, known as protein corona fo
 rmation\, having impact not just on the NP itself\, but even more importan
 tly on the bound allergen. We have recently established a suite of in vitr
 o assays that elucidate effects at a structural and molecular level with a
  particular focus on responses specific for sensitized individuals\, to so
 rt out alterations in the allergic effector function. Data enrichment from
  in vitro experimentation may be accomplished by use of suitable in silico
  modeling tools. Therefore\, protein corona prediction was tested and eval
 uated for its potential to complement the experimental workflow. Ultimatel
 y\, combined in vitro and in silico data including comprehensive metadata 
 was uploaded to the NanoCommons Knowledge Base to aid data FAIRness\, i.e.
  Findability\, Accessibility\, Interoperability\, and Reusability. In conc
 lusion\, such integrated workflows can help in early-stage decision-making
  processes in therapeutic development\, and hence\, promote safe-by design
  approaches in nanomedical innovation\, as well as – in combination with
  in silico-based exposure-relevant dose-finding – serve for risk monitor
 ing at specifically loaded areas\, e.g.\, workplaces\, taking into account
  pre-existing conditions such as allergic sensitization. Acknowledgments: 
 This work was supported by the international PhD program “Immunity in Ca
 ncer and Allergy - ICA” of the Austrian Science Fund (FWF\, grant no. W0
 1213)\, the EU H2020 projects NanoRigo and NanoCommons (grant no.s 814530 
 and 731032\, respectively)\, and the Allergy-Cancer-BioNano (ACBN) Researc
 h Center of the Paris Lodron University of Salzburg (PLUS).
SUMMARY:56th Eurotox Conference - Personalized nano-immunotoxicology for th
 e workplace
URL;VALUE=URI:https://infrastructure.nanocommons.eu/events/53/56th-eurotox-
 conference-personalized-nano-immunotoxicology-for-the-workplace/
END:VEVENT
END:VCALENDAR